AMIODARONE-INDUCED THYROID DYSFUNCTION: CLINICAL CASE WITH LITERATURE REVIEW

Keywords: amiodarone, thyroid dysfunction, diagnosis, treatment

Abstract

The article addresses the problem of amiodarone-induced thyroid dysfunction based in the clinical case. The literature data on the pathogenesis, diagnosis of this disease, as well as management tactics for different variants of amiodarone-associated thyroid dysfunction are shown.

Transient changes in thyroid function tests often occur in euthyroid individuals treated with amiodarone. Amiodarone causes predictable changes of tests that characterize the function of the thyroid gland, explicable in terms of physiological effects, caused by an iodine excess and its inhibition of deiodinase activity. Identify euthyroid hypothyroxinemia should not be considered as an indication for the abolition of amiodarone. While patients with pre-existing autoimmune thyroid disease (subclinical Hashimoto's thyroiditis or positive antithyroid antibodies) are at increased risk of developing amiodarone-induced hypothyroid-dism, most patients remain euthyroid during amiodarone therapy. Since small increases in serum TSH concentrations (10 to 20 mU/L) are seen in euthyroid patients for the first three to six months after amiodarone therapy is initiated, amiodarone-induced hypothyroidism should only be diagnosed when serum T4 concentrations are low-normal or low, or mild TSH elevation persists.

Downloads

Download data is not yet available.

Author Biography

L. V. Bogun, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Svobody sq., 6, Kharkiv, 61022, Ukraine

 

References

Singh B. N. Amiodarone as paradigm for developing new drugs for atrial fibrillation / B.N. Singh // J Cardiovasc Pharmacol. – 2008. – № 4. – p. 300–305.

Hudzik B. Amiodarone-related thyroid dysfunction / B. Hudzik, B. Zubelewicz-Szkodzinska // Intern Emerg Med. – 2014. – № 9. – p. 829–839.

Loh K. C. Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review / Loh Keh-Chuan // Postgrad Med J. – 2000. – № 893. – p. 133–140.

Rao R.H. Iodine kinetic studies during amiodarone treatment / R.H. Rao, V.R. McCready, G.S. Spathis // J Clin Endocrinol Metab. – 1986. – № 62. – p. 563–568.

Stanbury J. B. Iodine-induced hyperthyroidism: Occurrence and epidemiology / J.B. Stanbury, A.E. Ermans, P. Bourdoux et al. // Thyroid. – 1988. – № 8. – p. 83–100.

Narayana S. K. Management of Amiodarone-Related Thyroid Problems / S. K. Narayana, D. R. Woods, C. J. Boos // Ther Adv Endocrinol Metab. – 2011. – № 3. – p. 115–126.

Harjai K. J. Amiodarone-induced hyperthyroidism: A case series and brief review of literature / K. J. Harjai, A. A. Licata // Pacing Clin Electrophysiol. – 1996. – № 19. – p. 1548–1554.

Bogazzi F. Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis / F. Bogazzi, E. Martino, E. Dell'Unto et al. // Eur J Endocrinol Invest. – 2003. – № 26. – p. 635–640.

Vanbeeren H. C. Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha-1 receptor protein / H. C. Vanbeeren, O. Bakker, W. Wiersinga // Mol Cell Endocrinol. – 1995. – № 112. – p. 15–19.

Braverman L. E. Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease/L. E. Braverman, S. H. Ingbar, A. G. Vagenakis et al. //J Clin Endocrinol Metab. – 1971. - № 32. – p. 515–521

Amico J. A. Clinical and chemical assessment of thyroid function during therapy with amiodarone / J. A. Amico, V. Richardson, B. Alpert et al. // Arch. Intern. Med. – 1984. – №. 144. – p. 487–490.

Fradkin J. E. Iodide-induced thyrotoxicosis / J. E. Fradkin, J. Wolff // Medicine (Baltimore). – 1983. – № 62. – p.1–20

Trip M. D. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism / M. D. Trip, W. Wiersinga, T. A. Plomp // Am J Med. – 1991. - № 91. – p. 507–511

Nademanee K. Amiodarone and thyroid function / K. Nademanee. R. W. Piwonka, B. N. Singh // Hershman Prog Cardiovasc Dis. – 1989. – № 31. – p.427–437

Martino E. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases/ E. Martino, F. Aghini-Lombardi, S. Mariotti et al. Clin Endocrinol (Oxf). – 1987. – № 26. – p.227–237

Ursella S. Amiodarone-induced thyroid dysfunction in clinical practice / S. Ursella, A. Testa, M. Mazzone, N. Gentiloni Silveri // European Review for Medical and Pharmacological Sciences. – 2005. – № 10. – p. 269–278

Basaria S. Amiodarone and the thyroid / S. Basaria, D.S. Cooper // Am J Med. – 2005. – № 118. – p. 706–714

Newman C. M. Amiodarone and the thyroid: A practical guide to the management of thyroid dysfunction induced by amiodarone therapy / C. M. Newman, A. Price, D. W. Davies et al. // Heart – 1998 – № 79. – p. 121–127

Siddoway L. A. Amiodarone: Guidelines for use and monitoring / L. A. Siddoway // Am Fam Phys. – 2003. – № 68. – p. 2189–2196

Martino E. Short term administration of potassium perchlorate restores euthyroidism in amiodarone-induced hypothyroidism / E. Martino, S. Mariotti, F. Aghini-Lombardi et al. // J Clin Endocrinol Metab. – 1986. – № 63. – p.1233–1236

van Dam E. W.Treatment of amiodarone-induced hypothyroidism with potassium perchlorate / E. W. van Dam, M. F. Prummel, W. M. Wiersinga, R. E. // Nikkels Neth J Med. – 1993. – № 42. – p. 21–24

De Groef B.Perchlorate versus other environmental sodium / iodide symporter inhibitors: potential thyroid-related health effects / B. De Groef, B. R. Decallonne, S. Van der Geyten et al // European Journal of Endocrinology. – 2006. – № 1. – p. 17–25

Martino E. Amiodarone: a common source of iodine-induced thyrotoxicosis / E. Martino, F. Aghini-Lombardi, S. Mariotti et al. // Horm Res. – 1987. – № 26. – p. 158–171.

How to Cite
Bogun, L. V. (1). AMIODARONE-INDUCED THYROID DYSFUNCTION: CLINICAL CASE WITH LITERATURE REVIEW. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (32), 62-67. https://doi.org/10.26565/2227-6505-2016-32-10